Evidence map›Paper›PMID 28694463›Full record

ArticleScientific reports2017

Contrast-enhanced MR microscopy of amyloid plaques in five mouse models of amyloidosis and in human Alzheimer's disease brains.

Clémence Dudeffant, Matthias Vandesquille, Kelly Herbert, Clément M Garin, Sandro Alves, Véronique Blanchard, Emmanuel E Comoy, Fanny Petit, Marc Dhenain

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Zero Echo TimeMetabolites · 2021
    Article
  14. Article
  15. Article
  16. Neurophotonics · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Clémence DudeffantCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92260, Fontenay-aux-Roses, France.
Matthias VandesquilleCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92260, Fontenay-aux-Roses, France.
Kelly HerbertCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92260, Fontenay-aux-Roses, France.
Clément M GarinCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92260, Fontenay-aux-Roses, France.
Sandro AlvesINSERM U986, Université Paris-Sud, 94276, Le Kremlin-Bicêtre, France.
Véronique BlanchardSanofi, Translational Science Unit, Molecular Histopathology and Bioimaging, Chilly-Mazarin, France.
Emmanuel E ComoyCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), SEPIA, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Fanny PetitCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92260, Fontenay-aux-Roses, France.
Marc DhenainCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92260, Fontenay-aux-Roses, France. Marc.Dhenain@cea.fr.ORCID 0000-0001-8804-4101
Université Paris-Sud · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRSanofi (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gadolinium (Gd)-stained MRI is based on Gd contrast agent (CA) administration into the brain parenchyma. The strong signal increase induced by Gd CA can be converted into resolution enhancement to record microscopic MR images. Moreover, inhomogeneous distribution of the Gd CA in the brain improves the contrast between different tissues and provides new contrasts in MR images. Gd-stained MRI detects amyloid plaques, one of the microscopic lesions of Alzheimer's disease (AD), in APP

Indexed as

Alzheimer DiseaseAmyloidosisAnimalsAutopsyContrast MediaDisease Models, AnimalGadoliniumHumansIronMagnetic Resonance ImagingMiceMice, TransgenicPlaque, AmyloidContrast MediaGadoliniumIron

Identifiers

PMID28694463
PMCPMC5504006
OpenAlexW2727977265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.